Anmol Awan
Research Subjects
Research Interests
Anmol Awan has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Afnan Ahmad Qureshi
Department of Internal Medicine, Wah Medical College, Wah Cantt, Pakistan
1 shared publication - Ailiya Batool
Department of Internal Medicine, Wah Medical College, Wah Cantt, Pakistan
1 shared publication - Huzaifa Mahmood
Department of Internal Medicine, Wah Medical College, Wah Cantt, Pakistan
1 shared publication - Muhammad Adnan Qamar
Spinghar medical University, Kabul, Afghanistan
1 shared publication - Muhammad Zaid Saeed
Department of Internal Medicine, Wah Medical College, Wah Cantt, Pakistan
1 shared publication
Latest Publications
- Open Access
- 20 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (5) , 2990-2991
Copper-histidine therapy: a targeted metabolic intervention for Menkes disease
Menkes disease (MD) is a rare, X-linked recessive disorder of copper metabolism, characterized by progressive neurodegeneration, connective tissue abnormalities, and the distinctive phenotype of pili torti. The disease is caused by pathogenic variants in the ATP7A gene, which encodes a copper-transporting P-type ATPase essential for cellular copper efflux and delivery of copper to secreted cuproenzymes. Severe forms of MD typically present in early infancy and are associated with rapid neurological decline and death within the first 3 years of life. Currently, therapeutic options are limited, and outcomes are highly dependent on the timing of intervention. Copper-histidine represents a biologically rational intervention designed to bypass defective intestinal copper transport and restore systemic copper availability. Experimental and clinical observations suggest that early administration may partially correct copper deficiency, improve biochemical parameters, and, in selected cases, alter neurological outcomes and survival. This letter summarizes the pathophysiological basis of MD, the rationale for copper-histidine therapy, and the existing evidence supporting its potential role as a disease-modifying intervention when initiated early in life.
- 20 April 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (5) , 2990-2991
Open AccessCopper-histidine therapy: a targeted metabolic intervention for Menkes disease
Menkes disease (MD) is a rare, X-linked recessive disorder of copper metabolism, characterized by progressive neurodegeneration, connective tissue abnormalities, and the distinctive phenotype of pili torti. The disease is caused by pathogenic variants in the ATP7A gene, which encodes a copper-transporting P-type ATPase essential for cellular copper efflux and delivery of copper to secreted cuproenzymes. Severe forms of MD typically present in early infancy and are associated with rapid neurological decline and death within the first 3 years of life. Currently, therapeutic options are limited, and outcomes are highly dependent on the timing of intervention. Copper-histidine represents a biologically rational intervention designed to bypass defective intestinal copper transport and restore systemic copper availability. Experimental and clinical observations suggest that early administration may partially correct copper deficiency, improve biochemical parameters, and, in selected cases, alter neurological outcomes and survival. This letter summarizes the pathophysiological basis of MD, the rationale for copper-histidine therapy, and the existing evidence supporting its potential role as a disease-modifying intervention when initiated early in life.